Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an update.
Neuren Pharmaceuticals Limited has announced the application for the quotation of 1,500,000 ordinary fully paid securities on the ASX. This move is part of the company’s strategy to enhance its capital structure and potentially increase its market presence, providing more liquidity and opportunities for stakeholders.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$29.75 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing therapies for neurodevelopmental disorders. The company is known for its work on treatments targeting conditions such as Rett syndrome and Fragile X syndrome.
Average Trading Volume: 544,918
Technical Sentiment Signal: Buy
Current Market Cap: A$1.94B
For an in-depth examination of NEU stock, go to TipRanks’ Overview page.